Subtype
Cervical Neoplasm
CI-CAN-00004801Explore in graph →
Non-malignant573 active trials4 approved drugs14 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004801Explore in graph →
Clinical trials
2,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05595252 | Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022 | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 1 | Oct 26, 2022 |
| NCT05531981 | Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer | unknown | — | 350 | Peking Union Medical College HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05570331 | Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women | unknown | — | 2,200 | Ding MaOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05561413 | Gynaecology Exercise and Mindfulness Study(GEMS) | unknown | N/A | 40 | University of UlsterOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05560035 | The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery | unknown | N/A | 60 | General Hospital of Ningxia Medical UniversityOTHER | 0 | Sep 29, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05536843 | Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests(TTMV HPV DNA) | unknown | — | 500 | University of Mississippi Medical CenterOTHER | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05532930 | An Exploratory Study of Using Magnetic Resonance Prognostic Imaging Markers for Radiotherapy In Patients With Cervix Cancer (EMPIRIC Study)(EMPIRIC) | unknown | — | 40 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05142397 | The Dynamic Process of VMB and Mucosal Immunity After FUS Treatment of CIN Patients With Fertility Requirement | unknown | — | 90 | Shufang ChangOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04484415 | Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)(APRICITY) | unknown | Phase 3 | 402 | Asieris MediTech (Hong Kong) Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05475847 | Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer(TIL) | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 49 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 48 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT04742543 | Virtual Reality During Conization of Cervix Uterus Under Local Anesthesia | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04772001 | Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer | unknown | N/A | 53 | Zhongnan HospitalOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT05362669 | SMS Messaging for Invitation in the Cervical Cancer Screening Programme(CERCA-SMS) | unknown | N/A | 450 | Institut Català d'OncologiaOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05359913 | Podcasting Cervical Cancer Prevention for AAW | unknown | N/A | 40 | University of HoustonOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05314907 | Acceptability of Self-sampling for Cervical Cancer Screening | unknown | N/A | 1,614 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05310305 | PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer | unknown | — | 20 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05310383 | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | unknown | Phase 2 | 58 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05309122 | Cervical Cancer Screening Strategies | unknown | — | 10,000 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310331 | Donafenib for Recurrent Cervical Cancer | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05259540 | Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | unknown | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05290428 | DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening | unknown | — | 459 | Peking Union Medical College HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | unknown | Phase 2 | 122 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT03955367 | Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer | unknown | Phase 3 | 638 | Peking Union Medical College HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05236855 | Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening | unknown | — | 200 | IWK Health CentreOTHER | 0 | Feb 11, 2022 | clinicaltrials |
| NCT05234905 | H101 Combined With Camrelizumab for Recurrent Cervical Cancer | unknown | Phase 2 | 55 | Zhejiang Cancer HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05225493 | HIV Indicator Diseases in Hospital and Primary Care(#AwareHIV) | unknown | — | 1,500 | Erasmus Medical CenterOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05210348 | Clinical Evaluation of Detection of High Risk HPV in Urine(Urine-hrHPV) | unknown | — | 1,000 | Peking University People's HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05185713 | The Mechanism of Vaginal Flora and Its Metabolites in the Pathogenesis of Cervical Cancer | unknown | — | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT04371887 | Comparing Strategies for Implementing Primary HPV Screening | unknown | N/A | 45,000 | Chun ChaoOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05105672 | A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167149 | Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer | unknown | N/A | 144 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 28, 2022source: clinicaltrials